Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Look for a nice pop up tomorrow morning, the CEO (Jennifer Bath) will have a live interview on BNN Bloomberg in Canada. It's at 11:30 am Eastern, 8:30 Pacific. Interview happening during trading session.
Dr. Jennifer Bath, CEO of @ImmunoPrecise will be Live Oct. 4th 7:15amET on
@foxandfriends
@FoxNews
You have it right. Hearing it is very close to release. I hope they take into consideration the holiday period. I think people will be pleased with what they find. They should be on Nasdaq, I think in the very near future. Which to me means they will meet the valuation requirements. I am sure institutional investors will be clamoring to get a piece of the action which will only push the valuation even higher. They are probably already talking to these institutional investor groups already since their goal for the year is to get on Q exchange and will need them for a financing in the US.
Hang in there. We are very close. Good luck.
Hello, Py
Sorry have not been around. Yes, that's what I have been hearing around here in the True North and strong....land of snow (lot's of it too). The data should be out soon, I am thinking before end of net week. The only thing is they may want to delay it by a week to get through Canada Day July 1 and July 4th holidays. The functional data is what this a very exciting play. The dips were nice for some to pick up. Cormack (brokerage) was buying up everything or most of the shares this past week. Everyone, waiting for the data anxiously. I think the data will be good since they already have a couple of collaboration types of agreements already. Connected to major Pharma with IPA will see great upside. Hold tight!!!
I agree. Immunoprecise mentioned in the following article with all the big boys!!!
https://3wnews.org/uncategorised/1227777/latest-news-2020-global-covid-19-therapeutic-market-by-coronavirus-covid19-impact-analysis-with-top-manufacturers-analysis-top-players-cadila-healthcare-johnson-johnson-immunoprecise-nova/
Damn, you sniffed out our secret, Shurth. Py we got company. Nice to have you on board. You will be very happy. Hope you got a pile of this in your kitty. This is an easy $4 US, but I think it will be much more than that. Only around 70 Million float including around 23% owned by insiders. Good Luck.
Hi Py,
Yes, I hear lot's of GOOD news flow is comming very soon. Keep your seat belt on!!!
Yes, it was the same up north too. I picked up another 10 K shares. News is out.
ImmunoPrecise Collaborates with the NIH and Integrated Biotherapeutics to Study the Structural Details of Antibodies with Therapeutic Potential to Treat or Prevent Coronavirus Disease 2019 (COVID-19)
VICTORIA, BC, June 4, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced it is collaborating, pursuant to an agreement dated May 14, 2020, in a multi-company effort with the laboratory of Dr. Frederick Dyda at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH), and Dr. M. Javad Aman at Integrated Biotherapeutics (IBT), to better understand the molecular binding interactions of potential therapeutic antibody candidates resulting from IPA's SARS-CoV-2 programs aimed at treating or preventing COVID-19.
This research consortium unites three reputable teams for lead antibody characterization, using Cryogenic Electron Microscopy (Cryo-EM) to determine the structural details of antibodies bound to the spike protein from the SARS-CoV-2 virus. IBT will provide the well-characterized trimeric spike protein ectodomain and the receptor binding domain (RBD) against which IPA's antibodies will be characterized using Cryo-EM performed in Dr. Dyda's laboratory.
Cryo-EM is a microscopy technique that uses an electron beam as its primary energy source (instead of a light beam), which allows for much greater resolution and magnification than with a traditional microscope and is emerging as a mainstream technique in structural biology. An initial cooling of the sample to cryogenic temperatures enables determination of the macromolecular structures under analysis, in this case, the atomic resolution that can be used to elucidate the precise epitopes targeted by IPA's antibodies in their molecular binding interactions with the SARS-CoV-2 spike protein. The data will shed light on the Company's understanding of how their lead candidate antibodies neutralize the virus that is causing COVID-19.
"The tripartite collaboration will deliver detailed, molecular-level understanding of how our lead antibodies interact with and neutralize the pathogenic SARS-CoV-2 spike protein", stated Yasmina Abdiche, CSO of ImmunoPrecise. "This information is critical in elucidating their mechanism of action and informing their combination into therapeutic cocktails that aim to provide potent and long-lasting protection against COVID-19 and emerging virus variants."
"We welcome this synergistic collaboration with ImmunoPrecise and the NIH towards delineation of critical sites of vulnerability in the SARS-CoV-2 that can lead to development of safe and effective immunotherapies for COVID-19", added M. Javad Aman, President and CSO of IBT.
It's a great piece of news. Totally a game changer. Could be licensed all over the world....WOW. Just think of the revenues that could flow from this. Apparently, this technology was successful with the Zika virus as noted in the NR. Just adds to the market cap to the company. I can only imagine what the next piece of news would be and where that would take us to. Sky's the limit. I am glad there are two rocket ships going up today - Space X and IPA...lol
NSERC Awards Grant to Fund Collaboration Between ImmunoPrecise and the University of Victoria for the Generation of a Potential COVID-19 Antibody-Based Test in Canada that can Provide Real-Time Responses
VICTORIA, May 27, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF), specialists in custom antibody discovery and development, today announced a collaboration between University of Victoria ("UVic")-based laboratory of Dr. Alexandre Brolo, experts in the development of novel diagnostic tools, and ImmunoPrecise Antibodies. The objective of this partnership is to develop a colorimetric antibody-based test for the detection and screening of COVID-19. Although most immunoassays are developed for blood or serum, this team is aiming to use patient saliva. The goal is to enable the test to be realized with an easily obtainable sample, which should be suitable for a home-test kit. The color change readout will be measured using a cell phone camera and analyzed by a custom cell phone application. The results, including the general location (by zone rather than by specific household, to comply with privacy rights) of the test, can be uploaded to a cloud-hosted database. This will provide immediate information about the number of infections and the general locations to the health authorities. The program builds on successful technology previously developed by Dr. Brolo's laboratory for the detection of the Zika virus. This previous technology demonstrated positive results in a pilot field study performed in Brazil, which verified the technology's ability to detect Dengue/Zika proteins using patient saliva samples.
"While the diagnostic testing is only one portion of IPA's overall Coronavirus program, the need for a highly reliable, quick and easy to administer diagnostic is an unmet need, and the laboratory of Dr. Brolo has the expertise and game plan we are honored to contribute to", stated Dr. Jennifer Bath, President and CEO of IPA.
Monoclonal, highly specific antibodies are the main component required for the development of immunoassays. The antibodies for this project will be generated using IPA's unique proprietary B cell Select™ platform. The high affinity and selectivity of the resulting antibodies will enable tests with no-cross-reactivity, low background, and enhanced detection. IPA and Dr. Brolo's group will work together to establish the most appropriate targets for the COVID-19 detection and to secure patient samples for validating the tests.
"We are interested in partnering with the Brolo group to speed up the application of these antibodies in a colorimetric antibody-based test for the detection and screening of COVID-19", explains Dr. Barry Duplantis, Canada project lead for diagnostics. "We have the expertise and networks to support the commercialization of the detection technology that incorporates our monoclonal antibodies".
The one-year NSERC award consists of a $50,000 grant to the Brolo laboratory. ImmunoPrecise will provide the antibodies to be used in the kit and will retain an exclusive option on the commercialization rights. Reasonable commercial terms will enable IPA to efficiently bring the technology to market and reach those in need quickly. All agreements will align with NSERC and UVic intellectual property and research policies and ensure utilization of results of this research for the benefit of Canada and Canadians, with the submission of research results in open access, peer-reviewed literature.
IPA and UVic are already working within their respective roles on the COVID-19 diagnostic platform. IPA is actively engaged in the process of screening antibody panels already under development, to determine which antibodies best meet the profile for those required in the diagnostic kit. The antibodies will then be tested against SARS-CoV-2 spike protein and validated using both convalescent and naïve, human patient samples. Validation of the portable diagnostic will then require approval by Health Canada prior to field tests and / or commercialization.
Additional Debenture Issuance
The Company also announces that further to its non-brokered private placement (see news release dated May 15, 2020) it has issued an additional CAD $35,000 of 10% convertible debentures. In total, the Company issued CAD $2,627,000 of convertible debentures on the financing.
The debentures issued under this tranche are unsecured, bear interest at a rate of ten percent (10%) per year, payable annually, and are due May 22, 2022 (which may be repaid early at the option of the Company). The principal amount of the debentures may be convertible, at the option of the holder, into shares of the Company at a conversion price of CAD $0.85 per share. The Company may force convert the principal amount of the debentures at CAD$0.85 per share if the average closing price is equal to or greater than CAD $1.50 for 20 trading days. In order to exercise this right, the Company must issue a news release announcing its intention to exercise this right within 10 business days after the end of the particular 20-day period.
The securities under this tranche are subject to restrictions on resale expiring on September 16, 2020. The Company paid a finder's fee totaling $1,750 under this final tranche.
About Brolo Group
Dr. Alexandre G. Brolo is a professor at the University of Victoria in Canada where he directs an innovative, multidisciplinary, and high-impact research program that spans the areas of nanotechnology, surface spectroscopy, electrochemistry and bioanalytical chemistry. Dr. Brolo's research is centered on the optical and spectroscopic properties of metallic nanostructures that support a physical phenomenon called "surface plasmon excitation". His work explores the fabrication, characterization, and application of these metallic nanostructures in biosensing and in enhanced spectroscopy, particularly in their use for remote chemical sensing and in combination with microfluidics. Dr. Brolo has published more than 150 research papers in top international journals and conference proceedings and presented on numerous occasions.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe. For further information, visit www.immunoprecise.com or contact solutions@immunoprecise.com. There is no assurance that ImmunoPrecise will be successful in the development of a diagnostic for the new Coronavirus.
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute "forward-looking statements" within the meaning of applicable Canadian securities laws. The Company uses words such as "may", "would", "could", "will", "likely", "expect", "believe", "intend" and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise's expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise's actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise's annual management discussion and analysis for the last quarter of the fiscal year ended January 31, 2020 which can be accessed at www.sedar.com. The "forward-looking statements" contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE ImmunoPrecise Antibodies
SOURCE ImmunoPrecise Antibodies Ltd.
https://www.prnewswire.com/news-releases/nserc-awards-grant-to-fund-collaboration-between-immunoprecise-and-the-university-of-victoria-for-the-generation-of-a-potential-covid-19-antibody-based-test-in-canada-that-can-provide-real-time-responses-301065701.html
From Apr 30 NR Johnson & Johnson:
Expanded Antiviral Research
In addition to the vaccine development efforts, BARDA and Johnson & Johnson have also expanded their partnership to accelerate Janssen’s ongoing work in screening compound libraries, including compounds from other pharmaceutical companies.
https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use
Just 2 weeks after (Apr 14th) this J&J news release IPA announces the Janssens agreement. Reading in between the lines my gut feeling it will be Jannsens as partners. The good thing is that J&J is an american company and has received billions from the US Government. This would be a great partnership for IPA.
I really don't have any definitive answer but I'm hearing from some other investors that it is pretty imminent. It should not have taken them a lot of time to achieve what they are doing, given the massive mAB library they have and the use of AI to isolate the neutralizing anti bodies.
I am sure they are doing their due diligence before releasing the results rather than give prelim data and fail like Moderna and Sorrento. Hopefully, this keeps going up and when they release the research data we will be in the $ Billion market cap range.
I have to agree with you on lack of shares available. Will be a clear case of supply and demand. 1. Price will go through the roof. 2. Large financing deal with one of the institutions. A couple of houses that IPA had deals with previously got into the buying big time in the past weeks, namely Haywood Securities and Cormack. These houses have an insight into IPA as they did the deals before and if they are buying then that's another good sign of things to come. Also, the last major financing in 2018 has 9.1 Million warrants that expire in Sept. 2020, priced at $1.25. This alone will bring over $11 Million into the company's coffers. We have almost reached that threshold for conversions to start happening. As well, there are other previous financing's which have more warrants still o/s. You could see them here if not already done so:
https://tmxmatrix.com/company/IPA/financings
I am really looking forward to the next few weeks / months. Thanks for the article you shared. IPA has the know how and combined with AI it just makes them that much better. As well combination of the all the animal mAB Therapeutics just speeds up the game that much faster.
I am an optimistic, believe in IPA. This is their time to come to the plate and hit the home run.
The share price is still very reasonable for someone to get into IPA, given the potential but window of opportunity is narrowing day by day. I am glad I was able to get into this company long time ago (2+ years). This COVID is obviously none of us dreamt about, who would have thought we would be in the middle of this pandemic. I was just happy with what they were doing as a CRO working with 60 percent of the 20 largest Pharma's. As tragic this is for people dying or suffering from the virus I am really happy that we are in the right sector at the right time. In a way it is good to know that this company has the potential to find the therapeutic cure. I believe there partnership with Janssens will hook them with J&J. J&J has significant funding coming from the US Government for the COVID vaccine. IPA will have everything researched and will just have to pass on the results to J&J for clinical trials and vaccine production.
Yeah, It sure like that way. Something is definitely up. Get ready for the ride. This company is way under valued. I think it is because it is listed on the Canadian side and only on the OTC on the US side. Eventually, it needs to be listed on the big board down south.
Good luck.
Sim
Candidates: Coronavirus-neutralizing antibodies
Category: ANTIBODY
Type: PolyTope mAb Therapy™, a defined antibody combination designed to target multiple epitopes and mechanisms of viral evasion, and enabled by IPA’s discovery platforms (including B Cell Select™ and DeepDisplay™) and ImmunoPrecise subsidiary Talem Therapeutics’ access to the transgenic animal platform OmniAb® for direct generation of human antibodies.
Status: IPA said March 30 that its collaboration partner EVQLV submitted its first panel of candidate therapeutic antibody sequences, comprised of DNA sequences encoding for potentially therapeutic antibodies against SARS-CoV-2. The sequences were generated in less than one week using computational antibody design, which combines mathematics, statistics, and computer science to identify high-affinity antibodies.
IPA said it will review the antibody candidates, then select approximately 1,200 ideal candidates characterized and screened by EVQLV’s artificial intelligence, and validate the antibody candidates in vitro at IPA’s lab facilities. The companies said they will continue to work on additional panels of computationally generated sequence candidates against SARS-CoV-2.
Earlier last month, IPA announced its PolyTope mAb Therapy approach to developing a COVID-19 treatment. The company also spoke of potentially developing a vaccine for COVID-19, but has not announced any such effort since then.
On February 20, IPA said it designated Ilse Roodink, PhD, chairwoman of Talem’s scientific committee, as its Coronavirus Global Project Leader.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
? FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
? DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
? KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
? TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
https://www.genengnews.com/covid-19-candidates/immunoprecise-antibodies-ipa-and-evqlv/
Candidates: Coronavirus-neutralizing antibodies
Category: ANTIBODY
Type: PolyTope mAb Therapy™, a defined antibody combination designed to target multiple epitopes and mechanisms of viral evasion, and enabled by IPA’s discovery platforms (including B Cell Select™ and DeepDisplay™) and ImmunoPrecise subsidiary Talem Therapeutics’ access to the transgenic animal platform OmniAb® for direct generation of human antibodies.
Status: IPA said March 30 that its collaboration partner EVQLV submitted its first panel of candidate therapeutic antibody sequences, comprised of DNA sequences encoding for potentially therapeutic antibodies against SARS-CoV-2. The sequences were generated in less than one week using computational antibody design, which combines mathematics, statistics, and computer science to identify high-affinity antibodies.
IPA said it will review the antibody candidates, then select approximately 1,200 ideal candidates characterized and screened by EVQLV’s artificial intelligence, and validate the antibody candidates in vitro at IPA’s lab facilities. The companies said they will continue to work on additional panels of computationally generated sequence candidates against SARS-CoV-2.
Earlier last month, IPA announced its PolyTope mAb Therapy approach to developing a COVID-19 treatment. The company also spoke of potentially developing a vaccine for COVID-19, but has not announced any such effort since then.
On February 20, IPA said it designated Ilse Roodink, PhD, chairwoman of Talem’s scientific committee, as its Coronavirus Global Project Leader.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
? FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
? DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
? KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
? TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
https://www.genengnews.com/covid-19-candidates/immunoprecise-antibodies-ipa-and-evqlv/
Hi Py11,
Looks like news is on the way. The update should be on their AI partners and what they found as targets using this process. Also, its expected they will be able to get some of the research grants.
This is good company, lots happening and their should be a continuous news stream.
Looks like the message is out and already price is up another 20% today. Their is a public holiday in Canada so no trading going on. You should be able to pickup some tomorrow. Current price is still pretty low. Must remember the float is pretty small compared to companies like Sorrento.
This company is still at the ground level. Any news on Anti-body targets and research grants, we will not looking back. We are just waiting for the lift-off!!!
COVID 19 Play Low Market Cap
This company is ready for take-off.
ImmunoPrecise is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe,for its pharmaceutical clients. For further information, visit www.immunoprecise.com or contact solutions@immunoprecise.com.
Positive Ebita, ex Pfizer CSO , Rev 2 to 15 mill growth over the last 3 years, Janssens deal, working with 60% of the top 20 pharmas. Lots already going for this company, even before COVID. Has already linked up with an AI company. check it out and do your own due dilligence. Don't miss the boat!